These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35812822)

  • 41. Dual-agent dose-finding in Phase I clinical trial-An extension of rapid enrollment design.
    Wang Y
    Stat Med; 2024 Sep; 43(22):4361-4371. PubMed ID: 39075332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improving early phase oncology clinical trial design: A case study.
    Phillips AJ; Clark TP
    Pharm Stat; 2022 Nov; 21(6):1370-1375. PubMed ID: 35765820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
    Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
    Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries.
    Li C; Pan H
    PLoS One; 2020; 15(8):e0237254. PubMed ID: 32853204
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
    Liu R; Lin J; Li P
    Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Introduction of Oncology Dose-Finding Trial Designs].
    Takeda K
    Gan To Kagaku Ryoho; 2022 Apr; 49(4):365-370. PubMed ID: 35444116
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A hybrid design for dose-finding oncology clinical trials.
    Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
    Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bayesian optimal interval design with multiple toxicity constraints.
    Lin R
    Biometrics; 2018 Dec; 74(4):1320-1330. PubMed ID: 29870069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
    Wages NA; Conaway MR
    Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling.
    Su X; Li Y; Müller P; Hsu CW; Pan H; Do KA
    Pharm Stat; 2022 Nov; 21(6):1149-1166. PubMed ID: 35748220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tips for Accelerating BOIN Design.
    Kojima M; Wende W; Zhao H
    Ther Innov Regul Sci; 2024 Nov; 58(6):1129-1137. PubMed ID: 39222294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Impact of Early-Phase Trial Design in the Drug Development Process.
    Conaway MR; Petroni GR
    Clin Cancer Res; 2019 Jan; 25(2):819-827. PubMed ID: 30327310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.
    Lin R; Zhou Y; Yan F; Li D; Yuan Y
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33283133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
    Takeda K; Morita S; Taguri M
    Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
    Chen X; Zhang J; Jiang Q; Yan F
    J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CFO: Calibration-free odds design for phase I/II clinical trials.
    Jin H; Yin G
    Stat Methods Med Res; 2022 Jun; 31(6):1051-1066. PubMed ID: 35238697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.